Skip to main content
Clinical Trials/NCT02513875
NCT02513875
Completed
Not Applicable

Prevention of Type 2 Diabetes in Women With Prediabetes Using Vitamin D Supplementation and Lifestyle Intervention in North India (PREVENT-WIN Study)

Diabetes Foundation, India1 site in 1 country121 target enrollmentFebruary 2013
ConditionsPrediabetes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Prediabetes
Sponsor
Diabetes Foundation, India
Enrollment
121
Locations
1
Primary Endpoint
fasting glucose (mg/dL)
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

The work plan will have the following S&T components. Component 1: Cross-sectional Study

Cross-sectional study will be of 1.5 years where 400 women from rural will be screened randomly for the vitamin D deficiency and its determinants including duration of sun exposure.

Component 2: Prospective Study

This open-label randomized placebo-controlled trial would be done in 150 pre-diabetic women with vitamin D deficiency. The women will be recruited from cross-sectional study, out patient department and health camps and they will be followed up for 2 years. The women will be randomized into two groups; lifestyle modification counseling along with intervention with either vitamin D or placebo. The levels of vitamin D and blood glucose will be assessed periodically (every 6 months). In those having recurrent vitamin D deficiency, the course of vitamin D will be repeated. At the end of the study, incidence of T2DM in both groups will be compared.

Registry
clinicaltrials.gov
Start Date
February 2013
End Date
January 25, 2018
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Dr Anoop Misra

Principal Investigator

Diabetes Foundation, India

Eligibility Criteria

Inclusion Criteria

  • Healthy women aged 20-60 years.

Exclusion Criteria

  • Received Vitamin D or calcium supplementation in the previous six months.
  • On any medication within last one month which could potentially influence insulin secretion, insulin sensitivity, vitamin D or calcium metabolism (e.g. metformin, thiazolidenediones, steroids etc.) and on any medication that activate steroid and xenobiotic receptors, and drugs used in transplantation
  • Pregnancy and lactation at time of study
  • Severe end organ damage or chronic diseases: renal/hepatic failure, any malignancy, major systemic illness etc.
  • Known case of HIV infection.
  • Known case of diabetes mellitus and other endocrine disorders.

Outcomes

Primary Outcomes

fasting glucose (mg/dL)

Time Frame: 2 years

Secondary Outcomes

  • TC (mg/dL)(2 years)

Study Sites (1)

Loading locations...

Similar Trials